

RESEARCH ARTICLE

Open Access



Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

Greg W. Mattingly¹, Peter M. Haddad^{2,3,4,5}, Michael Tocco^{6*}, Jane Xu⁶, Debra Phillips⁶, Andrei Pikalov⁶ and Antony Loebel⁶

Abstract

Background: Patients with a diagnosis of schizophrenia are at an increased risk for developing metabolic syndrome, which is associated with greater cardiovascular morbidity and mortality. Treatment with some commonly used antipsychotic medications may increase the risk of developing metabolic syndrome. The aim of the study was to evaluate the safety of lurasidone in patients who continued lurasidone or switched from risperidone to lurasidone. A secondary aim was assessment of the effect of long term lurasidone on the Positive and Negative Syndrome Scale (PANSS).

Methods: The treatment sample in the current study consisted of clinically stable patients with schizophrenia ($N = 223$) who had completed a 12 month, double blind study of lurasidone vs. risperidone. In the current extension study, all patients received 6 months of open label treatment with lurasidone, either continuing lurasidone assigned during the preceding double blind trial, or switching from double blind risperidone to lurasidone. Safety and tolerability parameters included body weight, prolactin, and metabolic laboratory tests.

Results: Six months of OL treatment with lurasidone was generally well tolerated, with a low incidence of parkinsonism (4.5%) and akathisia (3.1%). Overall, few adverse events were rated as severe (4.9%), and discontinuation due to an adverse event was low in the lurasidone continuation vs. risperidone switch groups (3.7% vs. 6.9%). In the lurasidone continuation versus risperidone switch groups, change from OL baseline to 6 month endpoint (observed case) was observed in mean body weight (-0.6 vs. 2.6 kg), median total cholesterol (-4.0 vs. +4.5 mg/dL), triglycerides (-4.5 vs. 5.5 mg/dL), glucose (0.0 vs. 3.0 mg/dL) and prolactin (males, +0.15 vs. 11.2 ng/mL; females, +1.3 vs. 30.8 ng/mL). Improvement in PANSS total score was maintained, from OL baseline to endpoint in the continuation vs. switch groups (+1.0 vs. 1.0; OC).

Conclusions: In this 6 month extension study, lurasidone treatment was generally well tolerated and associated with minimal effects on weight, metabolic parameters, and prolactin levels. Patients who switched from risperidone to lurasidone experienced reductions in weight, metabolic parameters and prolactin levels commensurate with increases in these safety parameters experienced during the previous 12 months of treatment with risperidone.

Trial registration: ClinicalTrials.gov NCT00641745 (Date of Registration: March 24, 2008).

Keywords: Lurasidone, Antipsychotic agents, Schizophrenia, Adverse effects, Weight, Metabolic, Lipids, Prolactin

* Correspondence: paladinmed@gmail.com

⁶Sunovion Pharmaceuticals Inc., Fort Lee, NJ, 84 Waterford Dr, Marlborough, MA 01752, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Non-response to treatment with an initial antipsychotic occurs in at least 50% of patients with first episode schizophrenia and increases as the illness becomes more chronic and recurrent [1, 2]. The recommended next-step treatment option in non-responders is switching to an alternative antipsychotic [3, 4]. In addition to lack of efficacy, problems with safety or tolerability frequently necessitate switching antipsychotics [5].

Lurasidone is an atypical antipsychotic agent that has demonstrated efficacy in short-term [6–9] and long-term studies [10–12] of patients with schizophrenia, with a safety profile indicating minimal effects on weight, metabolic parameters, and prolactin [13, 14].

Previously, the effectiveness of switching patients with schizophrenia or schizoaffective disorder to lurasidone using 3 different dosing strategies has been evaluated [15]. At the time of the switch, patients were in a non-acute phase of their illness and were being treated with a wide range of typical or atypical antipsychotics. This 6-week study demonstrated that switching patients to lurasidone was associated with good efficacy and tolerability and low rates of treatment failure (8%), regardless of switching strategy (rapid or slow titration of lurasidone). Initial improvement in weight and lipids was observed after 6 weeks of treatment. In a 6-month, open-label extension of this study, improvements in efficacy on lurasidone were maintained, with minimal long-term effects on weight, metabolic parameters, and prolactin [16].

The effect on safety parameters of switching patients with schizophrenia from olanzapine to lurasidone has also been evaluated in a 6-month, open-label extension study in which patients who completed 6 weeks of double-blind, placebo-controlled treatment with olanzapine or lurasidone were switched to 6 months of open-label lurasidone 40–120 mg/d [17]. At 6-month endpoint, switching from olanzapine to lurasidone resulted in clinically meaningful ($\geq 7\%$) reduction in weight in 29.0% of patients; and median reduction in lipid parameters, including total cholesterol (-15.0 mg/dL) and triglycerides (-28.0 mg/dL).

We now report results of an open-label extension study in which patients with schizophrenia who completed a double-blind, 12-month study of lurasidone versus risperidone [18] either continued lurasidone or switched from risperidone to lurasidone for an additional 6 months of open-label treatment. Notable safety results for lurasidone vs. risperidone at endpoint of the initial double-blind study included: mean reduction in weight (-1.0 vs. $+1.5$ kg) and waist circumference (-0.6 vs. $+1.6$ cm); smaller mean increases in prolactin for females ($+34.9$ vs. 53.3 ng/mL) but similar increases for males (13.5 vs. 14.1 ng/mL).

The primary objective of this study was to evaluate the long-term safety, tolerability and overall effectiveness of

lurasidone in both the continuation and risperidone switch groups.

Methods

Study design

Detailed methods for the initial 12-month, double-blind study have been previously reported [18]. Briefly, clinically stable outpatients, ages 18–75 years, with a diagnosis of schizophrenia or schizoaffective disorder, were randomly assigned in a 2:1 ratio to receive lurasidone (flexibly dosed, 40–120 mg/d) or risperidone (flexibly dosed, 2–6 mg/d). Study completers were eligible to continue into the current 6-month, open-label extension study that was conducted from March 2009 to January 2011 at sites in the United States ($n = 40$), South Africa ($n = 7$), Argentina ($n = 5$), Chile ($n = 5$), Brazil ($n = 4$), Croatia ($n = 3$), Thailand ($n = 3$), and Israel ($n = 1$). To maintain the double-blind in the initial 12-month study, all patients entering the current open-label study received 3 days of single-blind placebo washout followed by 7 days of lurasidone 80 mg/d. After 7 days, the lurasidone dose could be titrated, based on the judgment of the investigator, in the range of 40–120 mg/d.

The study was conducted in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonisation and with the ethical principles of the Declaration of Helsinki. The study was approved by an institutional review board or independent ethics committee at each study site, and all patients provided written informed consent prior to initiation of study procedures. No important changes in study design or methodology were made after the study was initiated.

Assessments

Assessment visits occurred at baseline of the open-label extension study and monthly thereafter. Adverse events were based on patient self-report in response to an open-ended question or were based on investigator observation of changes in the patient during examination. Movement disorder symptoms were evaluated with the Simpson-Angus Scale (SAS) [19], Barnes Akathisia Rating Scale (BARS) [20], and Abnormal Involuntary Movement Scale (AIMS) [21]. Safety assessments included laboratory tests (chemistry and hematology panels, lipid panel, glycosylated hemoglobin [HbA1c], bone alkaline phosphatase, N-telopeptide, osteocalcin, parathyroid hormone, prolactin, and testosterone), electrocardiograms (ECG), physical examinations, and vital sign measurements. In a subset of patients (at selected US sites), bone mineral density assessments were performed (BMD, using dual-energy x-ray absorptiometry [DXA]). T-scores were calculated ($[\text{patient's BMD} - \text{mean BMD of sex-matched young adults}] / 1\text{-SD of young adults}$), and standard criteria

were used to determine BMD category (normal vs. osteopenia vs. osteoporosis) [22]. Ophthalmologic examinations, including dilated fundoscopic and slit lamp eye examinations, were also performed.

Efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS) [23], Clinical Global Impression, Severity scale [21], and the Montgomery-Åsberg Depression Rating Scale (MADRS) [24]. Training and certification of raters at each investigational site on study assessments was provided prior to initiation of the double-blind study.

Statistical analysis

The primary safety analysis population consisted of all patients who received at least one dose of lurasidone during the 6-month open-label extension study. All safety and efficacy outcomes were pre-specified and were analyzed for the overall treatment sample, and for 2 patient subgroups: patients who received lurasidone in the double-blind study, and patients who received risperidone in the double-blind study. Change scores were calculated from double-blind baseline to open-label study endpoint and from open-label baseline to open-label study endpoint (month 6). Observed cases (OC) and last observation carried forward (LOCF-endpoint) analyses were performed.

Results

Patient disposition and study treatment


Of the 236 patients who completed the initial 12-month double-blind study, 223 (94.5%) continued into the current open-label extension study. Overall, 90.1% of patients completed at least 3 months of open-label treatment with lurasidone, and 174/223 (78.0%) completed 6 months of treatment. Reasons for premature discontinuation included adverse events (11/223; 4.9%), withdrew consent (11/223; 4.9%), lost to follow-up (10/223; 4.5%), insufficient clinical response (8/223; 3.6%), and miscellaneous other reasons (9/223; 4.0%). Figure 1 summarizes patient disposition for the two pre-specified patient subgroups (based on double-blind treatment assignment in the initial double-blind study).

Patient characteristics were similar at open-label baseline in both the lurasidone continuation subgroup, and the risperidone-to-lurasidone switch subgroup (Table 1). The mean daily dose of lurasidone during open-label extension was 81.1 mg. Twenty-nine percent of patients (n = 65) received at least one concomitant medication, most commonly anxiolytics (22%), hypnotics/sedatives (18%), antidepressants (15%), and anticholinergics (13%).

Safety

Adverse events

The most commonly reported adverse events were headache (6.3%), psychotic disorder (5.4%), and parkinsonism



(4.5%; Table 2), with minimal differences between the lurasidone continuation versus risperidone switch groups. For both groups combined, a total of 11 patients (4.9%) experienced an adverse event rated as severe; and 10 patients (4.5%) experienced a serious adverse event, consisting of schizophrenia ($n = 3$), psychotic disorder ($n = 3$), ankle fracture ($n = 1$), lung carcinoma ($n = 1$), possible seizure ($n = 1$), attempted suicide ($n = 1$; patient recovered and completed the study), and a completed suicide ($n = 1$; on open-label day 22 in a patient who had previously received 12 months of double-blind lurasidone, and who was experiencing recurrent psychotic symptoms).

Extrapyramidal symptoms

In the combined patient groups, the proportion who reported an extrapyramidal symptom (EPS)-related adverse event during the extension study was 7.6%, and the proportion with akathisia was 3.1%. EPS-related adverse events reported in more than 1 patient were parkinsonism (4.5%) and dystonia (1.3%). The incidence of an EPS-related adverse event was similar in the lurasidone continuation versus risperidone switch groups (Table 2). No patient discontinued due to an EPS-related adverse event or akathisia. Mean change from open-label baseline to study endpoint (LOCF) was 0.0 on the Simpson-Angus Scale, 0.0 on the Barnes Akathisia Rating Scale global clinical assessment of akathisia, and + 0.3 on the Abnormal Involuntary Movement Scale total score.

Table 1 Patient Characteristics (Open-Label Baseline, Safety Population)

Characteristic	LUR LUR ^a (N = 136)	RIS LUR ^b (N = 87)
Male, n (%)	102 (75.0)	58 (66.7)
Age, mean (SD), y	43.9 (10.7)	42.8 (10.8)
Race, n (%)		
White	50 (36.8)	39 (44.8)
Black	67 (49.3)	40 (46.0)
Asian	6 (4.4)	1 (1.1)
Other	13 (9.6)	7 (8.0)
Ethnicity, Hispanic/Latino, n (%)	36 (26.5)	25 (28.7)
Duration of illness, mean (SD), y	16.9 (10.7)	17.6 (11.9)
≥4 hospitalizations, n (%)	30 (22.1)	25 (28.8)
PANSS total score, mean (SD)	55.4 (13.6)	55.5 (11.2)
CGI S score, mean (SD)	2.8 (0.8)	2.9 (0.8)
MADRS score, mean (SD)	5.1 (5.6)	4.3 (4.4)

CGI S Clinical Global Impression Severity Scale, LUR lurasidone, MADRS Montgomery Åsberg Depression Rating Scale, PANSS Positive and Negative Syndrome Scale, RIS risperidone, SD standard deviation

^a Patients who received lurasidone in both double blind and open label studies

^b Patients who received risperidone during the double blind study and were switched to lurasidone in the open label study

Table 2 Adverse Events Reported in ≥2% of Patients During Open-Label Treatment With Lurasidone

Adverse Event, n (%)	LUR LUR ^a (N = 136)	RIS LUR ^b (N = 87)
≥1 adverse event	80 (58.8)	51 (58.6)
Headache	7 (5.1)	7 (8.0)
Psychotic disorder	6 (4.4)	6 (6.9)
Parkinsonism	5 (3.7)	5 (5.7)
Anxiety	2 (1.5)	6 (6.9)
Blood creatine phosphokinase increased	5 (3.7)	3 (3.4)
Insomnia	3 (2.2)	5 (5.7)
Nasopharyngitis	5 (3.7)	3 (3.4)
Akathisia	5 (3.7)	2 (2.3)
Somnolence	5 (3.7)	2 (2.3)
Influenza	6 (4.4)	1 (1.1)
Nausea	3 (2.2)	3 (3.4)
Upper respiratory infection	6 (4.4)	0 (0)
Vomiting	3 (2.2)	3 (3.4)
Back pain	2 (1.5)	3 (3.4)
Decreased appetite	3 (2.2)	2 (2.3)
Weight decreased	4 (2.9)	1 (1.1)

LUR lurasidone, RIS risperidone

^a Patients who received lurasidone in both double blind and open label studies

^b Patients who received risperidone during the double blind study and were switched to lurasidone in the open label study

Body weight, BMI, waist circumference

Mean weight, BMI, and waist circumference were reduced, from double-blind to open-label baseline, in patients who received 12 months of treatment with lurasidone (− 1.1 kg, − 0.55 kg/m², and − 0.4 cm, respectively), and were increased in patients who received 12 months of treatment with risperidone (+ 2.4 kg, + 2.1 kg/m², + 2.8 cm, respectively; Table 3; Fig. 2).

Mean changes in mean weight, BMI, and waist circumference at 6-month open-label endpoint (OC analysis) were minimal in the lurasidone continuation subgroup; in contrast, notable reductions were observed in the subgroup that switched from risperidone to lurasidone (− 2.9 kg, − 1.0 kg/m², − 1.6 cm, respectively; [OC]); and the proportion of patients who experienced ≥7% weight loss was 19.7%; Table 3).

Metabolic parameters

Median total cholesterol, triglycerides, and glucose were reduced, from double-blind to open-label baseline, in patients who received 12 months of treatment with lurasidone (− 8.5 mg/dL, − 13.0 mg/dL, − 1.0 mg/dL, respectively); and in patients who received 12 months of treatment with risperidone, median triglycerides and glucose were minimally increased (+ 1.0 mg/dL, + 3.0 mg/dL, respectively), while total

Table 3 Change From Double-blind Baseline in Safety Parameters After 12-months of Treatment With Lurasidone or Risperidone, Followed by 6-months of Open-label Treatment With Lurasidone (OC analysis)

Parameter	LUR LUR	RIS LUR
Weight, kg	n = 109^a	n = 66^a
DB Baseline mean (SD)	81.1 (18.25)	82.9 (18.65)
Mean change to OL Baseline (after 12 mo DB Tx)	1.1	+ 2.4
Mean change from OL Baseline to Month 6 OL	0.6	2.9
≥ 7% weight increase from DB Baseline, %	12.8	13.6
≥ 7% weight decrease from DB Baseline, %	28.4	18.2
≥ 7% weight increase from OL Baseline, %	1.8	3.0
≥ 7% weight decrease from OL Baseline, %	6.4	19.7
Body mass index, kg/m²	n = 109	n = 66
DB Baseline mean (SD)	27.7 (5.3)	28.8 (5.6)
Mean change to OL Baseline (after 12 mo DB Tx)	0.55	+ 2.1
Mean change from OL Baseline to Month 6 OL	0.2	1.0
Waist circumference, cm	n = 104	n = 62
DB Baseline mean (SD)	93.8 (14.1)	97.5 (14.3)
Mean change to OL Baseline (after 12 mo DB Tx)	0.4	+ 2.8
Mean change from OL Baseline to Month 6 OL	0.9	1.6
Total cholesterol, mg/dL	n = 108	n = 64
DB Baseline mean (SD)	196.4 (45.4)	188.0 (49.0)
Median change to OL Baseline (after 12 mo DB Tx)	8.5	9.0
Median change from OL Baseline to Month 6 OL	4.0	+ 4.5
Triglycerides, mg/dL	n = 108	n = 64
DB Baseline mean (SD)	127.5 (57.7)	125.5 (88.8)
Median change to OL Baseline (after 12 mo DB Tx)	13.0	+ 1.0
Median change from OL Baseline to Month 6 OL	4.5	5.5
Glucose, mg/dL	n = 105	n = 63
DB Baseline mean (SD)	95.1 (14.5)	94.6 (13.7)
Median change to OL Baseline (after 12 mo DB Tx)	1.0	+ 3.0
Median change from OL Baseline to Month 6 OL	0.0	3.0
Hemoglobin A1c, %	n = 103	n = 63
DB Baseline mean (SD)	5.7 (0.4)	5.6 (0.4)
Median change to OL Baseline (after 12 mo DB Tx)	0.0	0.0
Median change from OL Baseline to Month 6 OL	0.0	0.0
Bone alkaline phosphatase, mcg/L	n = 106	n = 61
DB Baseline mean (SD)	13.6 (5.2)	13.9 (4.3)
Median change to OL Baseline (after 12 mo DB Tx)	0.9	0.3
Median change from OL Baseline to Month 6 OL	+ 1.5	0
N telopeptide (urine), nmol BCE/mmol creatinine	n = 104	n = 62
DB Baseline mean (SD)	41.2 (120.3)	37.0 (35.8)
Median change to OL Baseline (after 12 mo DB Tx)	+ 1.5	4.0
Median change from OL Baseline to Month 6 OL	1.0	+ 0.5
Osteocalcin, ng/mL	n = 104	n = 61
DB Baseline mean (SD)	5.25 (3.38)	5.70 (4.36)
Median change to OL Baseline (after 12 mo DB Tx)	0.85	1.0

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.